Maarten Ligtenberg
Founder
FF
Flindr (formerly Immagene)
Shutdownimmagene.nl
Website unreachable since Oct 28, 2026
Immagene operates a biotech platform focused on developing precision immuno-oncology treatments through personalized cancer immunotherapies targeting various cancer types. The company builds a pipeline of immunotherapies to meet the significant medical need for effective cancer treatments.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$21.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Christian Blank
Founder
Daniel Peeper
Founder
Product
Problem
Current cancer immunotherapies often lack precision, leading to off-target effects and limited efficacy across diverse patient populations and cancer types. A significant medical need remains for personalized cancer treatments that can effectively target tumors while minimizing harm to healthy tissues.
Solution
Immagene is developing a precision immuno-oncology platform to create personalized cancer immunotherapies. The company aims to build a pipeline of targeted immunotherapies designed to address the unmet need for effective and specific cancer treatments. By focusing on personalized approaches, Immagene seeks to enhance therapeutic outcomes and reduce adverse effects associated with traditional cancer therapies.
Target Audience
The primary target audience includes cancer patients who are not responding adequately to existing treatments, as well as oncologists and medical researchers seeking more effective and personalized therapeutic options.
Features
- Development of personalized cancer immunotherapies
- Targeted treatment approach for various cancer types
- Focus on enhancing therapeutic efficacy and reducing off-target effects
- Pipeline of novel immunotherapy candidates